This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This one is a difficult one. And Sophia Ambruso had created a nice one for NephMadness - so why mess with such a nice piece of work? Here it is:
Last week’s #AskASN was all about cardiorenal syndrome. We had a great turnout and really interesting discussion.
Take a look at this visual abstract about diuretic induced “worsening kidney function” (That’s cardiology-speak for AKI). The visual abstract was done by Michelle Lim, NSMC intern.
